Avandia
On August 14, 2007 the U.S. Food and Drug Administration (FDA) announced that a number of diabetes drugs -- including Avandia (rosiglitazone) -- would now carry "black box" warnings on the risk of heart failure associated with use of the drugs. The "black box" warning is FDA's strongest form of warning. In July 2007 an FDA advisory committee recommended that Avandia remain on the market despite evidence that use of the drug increases the risk of heart attacks.
Click on the links below for information on Avandia (rosiglitazone) and related legal issues:
Page last updated on September 12, 2007
